Back to Trades
Other4
Generate Biomedicines, Inc.
GENB
Total Value
$27.0M
Company Information
- Company Name
- Generate Biomedicines, Inc.
- Ticker Symbol
- GENB
- CIK
- 0002100782
Insider Information
- Name
- Nally Michael
- Role
- Insider
- Location
- SOMERVILLE, MA
Filing Details
- Filing Date
- Mar 2, 2026
- Transaction Date
- Feb 26, 2026
- Accession Number
- 0001193125-26-085883
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Common Stock | 658,327 | — | C | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Derivative | 844,595 | $16.00 | Grant/Award | $13.5M |
| Feb 26, 2026 | Derivative | 844,595 | $16.00 | Grant/Award | $13.5M |
| Mar 2, 2026 | Derivative | 1,000,000 | — | C | — |
Footnotes
- (F1)Each share of Series A Preferred Stock automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Series A Preferred Stock had no expiration date.
- (F2)The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- (F3)The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.
- (F4)The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.